# Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

> **NCT00319748** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer

## Interventions

- **DRUG:** 852A

## Key facts

- **NCT ID:** NCT00319748
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-12
- **Final completion:** 2008-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319748, "Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00319748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*